U.S. regulators have directed COVID-19 vaccine makers to target the JN.1-lineage XFG variant for the 2026–2027 fall campaign. Pfizer has already received European authorization and plans to ship its updated shot soon, with U.S. availability expected in the fall. Health systems and purchasing groups are now opening prebooking windows and advising clinics to prepare orders and workflows, while insurers have confirmed coverage for the new doses.

Globally, recommendations differ slightly: the World Health Organization advised a monovalent LP.8.1 antigen in May 2026, whereas U.S. advisors favored XFG. The European Medicines Agency also recommended XFG, leading to regional variations in vaccine composition. Experts note that declining viral surveillance and sequencing make precise strain selection harder, but current public documents and industry actions point to a fall launch without major delays.

For the public, the practical takeaway is that updated shots will be available in the U.S. starting fall 2026. Providers and federal agencies are already treating this timeline as firm, even as some strain decisions remain pending. The overall message: expect the new vaccines in time for the autumn respiratory season, with slight differences in formulation depending on where you live.